Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
Othman Al‐Sawaf(Integrated Oncology (United States)), Kirsten Fischer(Düsseldorf University Hospital), Eugen Tausch(Universität Ulm), Christian P. Pallasch(University of Cologne), Brenda Chyla(AbbVie (United States)), Sandra Robrecht(University of Cologne), Lukas P. Frenzel(University of Cologne), Martin Peifer(University of Cologne), Anna Maria Fink(University of Cologne), Matthias Ritgen(Goethe University Frankfurt), Michael Hallek(Integrated Oncology (United States)), Joseph N. Paulson(Applied Mathematics (United States)), Christof Schneider(Universität Ulm), Barbara Eichhorst(University of Cologne), Sandhya Balasubramanian, Can Zhang(Guizhou Normal University), Hyun Yong Jin(Scripps Research Institute), Karl‐Anton Kreuzer(University of Cologne), Yi Meng Chang(Roche (Canada)), Yoonha Choi(Ewha Womans University), Yanwen Jiang, Alex Kotak(Roche (United Kingdom)), Stephan Stilgenbauer(Universität Ulm)
Cited by 3
Related Papers
Multivariable association discovery in population-scale meta-omics studies
|PLoS Computational Biology|2021|2.5k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k